Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-12-2007 | Rapid Communication

Possible prognostic role of IL-17R in osteosarcoma

Authors: Maria Cristina Honorati, Luca Cattini, Andrea Facchini

Published in: Journal of Cancer Research and Clinical Oncology | Issue 12/2007

Abstract

Purpose

An intense vascularization of primary tumor mass is associated with a fatal outcome in various types of invasive solid tumors. Interleukin 17 (IL-17), a CD4+ T-cell-derived cytokine, stimulates some tumor cells to secrete angiogenic factors, among which venous endothelial growth factor (VEGF). We assessed whether the expression of IL-17 receptor (IL-17R) represents a marker for the metastasizing ability of osteosarcoma (OS), a very malignant bone tumor.

Methods

We immunoassayed the amount of VEGF secreted by three OS cell lines expressing IL-17R in differing amounts: HOS, MG63 and U-2 OS, and their sensitivity to IL-17 stimulation to secrete VEGF.

Results

U-2 OS, which best expresses IL-17R, secreted the highest amounts of VEGF and was the most sensitive to IL-17, whereas MG63 expressed the lowest level of IL-17R, secreted the lowest amount of VEGF and was not sensitive to IL-17. IL-17R expression correlated with VEGF secretion and IL-17 sensitivity. U-2 OS expressed the most dedifferentiated phenotype, which is associated with tumor malignancy.

Conclusions

These results suggest that IL-17R in OS might represent a marker of tumor metastasis potential.

Alexandrakis MG, Pappa CA, Miyakis S, Sfiridaki A, Kafousi M, Alegakis A, Stathopoulos EN (2006) Serum interleukin-17 and its relationship to angiogenic factors in multiple myeloma. Eur J Intern Med 17:412–416PubMedCrossRef

Ali NN, Rowe J, Teich NM (1996) Constitutive expression of non-bone/liver/kidney alkaline phosphatase in human osteosarcoma cell lines. J Bone Miner Res 11:512–520PubMedCrossRef

Axelson H, Fredlund E, Ovenberger M, Landberg G, Pahlman S (2005) Hypoxia-induced dedifferentiation of tumor cells—a mechanism behind heterogeneity and aggressiveness of solid tumors. Semin Cell Dev Biol 16:554–563PubMedCrossRef

Clover J, Gowen M (1994) Are MG-63 and HOS TE85 human osteosarcoma cell lines representative models of the osteoblastic phenotype? Bone 15:585–591PubMedCrossRef

Dubois S, Demetri G (2007) Markers of angiogenesis and clinical features in patients with sarcoma. Cancer 109:813–819PubMedCrossRef

Ek ET, Ojaimi J, Kitagawa Y, Choong PF (2006a) Does the degree of intratumoural microvessel density and VEGF expression have prognostic significance in osteosarcoma? Oncol Rep 16:17–23PubMed

Ek ET, Ojaimi J, Kitagawa Y, Choong PF (2006b) Outcome of patients with osteosarcoma over 40 years of age: is angiogenesis a marker of survival? Int Semin Surg Oncol 3:7PubMedCrossRef

El-Houseini ME, bdel-Azim SA, El-Desouky GI, bdel-Hady S, El-Hamad MF, Kamel AM (2004) Clinical significance of vascular endothelial growth factor (VEGF) in sera of patients with pediatric malignancies. J Egypt Natl Canc Inst 16:57–61PubMed

Folkman J, Kalluri R (2004) Cancer without disease. Nature 427:787PubMedCrossRef

Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353–364PubMedCrossRef

Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70PubMedCrossRef

Hasan J, Byers R, Jayson GC (2002) Intra-tumoural microvessel density in human solid tumours. Br J Cancer 86:1566–1577PubMedCrossRef

Honorati MC, Neri S, Cattini L, Facchini A (2003) IL-17 enhances the susceptibility of U-2 OS osteosarcoma cells to NK cell lysis. Clin Exp Immunol 133:344–349PubMedCrossRef

Honorati MC, Cattini L, Facchini A (2004) IL-17, IL-1beta and TNF-alpha stimulate VEGF production by dedifferentiated chondrocytes. Osteoarthritis Cartilage 12:683–691PubMedCrossRef

Honorati MC, Neri S, Cattini L, Facchini A (2006) Interleukin-17, a regulator of angiogenic factor release by synovial fibroblasts. Osteoarthritis Cartilage 14:345–352PubMedCrossRef

Kato T, Furumoto H, Ogura T, Onishi Y, Irahara M, Yamano S, Kamada M, Aono T (2001) Expression of IL-17 mRNA in ovarian cancer. Biochem Biophys Res Commun 282:735–738PubMedCrossRef

Kaya M, Wada T, Akatsuka T, Kawaguchi S, Nagoya S, Shindoh M, Higashino F, Mezawa F, Okada F, Ishii S (2000) Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 6:572–577PubMed

Krueger S, Haeckel C, Buehling F, Roessner A (1999) Inhibitory effects of antisense cathepsin B cDNA transfection on invasion and motility in a human osteosarcoma cell line. Cancer Res 59:6010–6014PubMed

Mikulic D, Ilic I, Cepulic M, Orlic D, Giljevic JS, Fattorini I, Seiwerth S (2004) Tumor angiogenesis and outcome in osteosarcoma. Pediatr Hematol Oncol 21:611–619PubMedCrossRef

Naumov GN, Bender E, Zurakowski D, Kang SY, Sampson D, Flynn E, Watnick RS, Straume O, Akslen LA, Folkman J, Almog N (2006) A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 98:316–325PubMedCrossRef

Numasaki M, Fukushi J, Ono M, Narula SK, Zavodny PJ, Kudo T, Robbins PD, Tahara H, Lotze MT (2003) Interleukin-17 promotes angiogenesis and tumor growth. Blood 101:2620–2627PubMedCrossRef

Numasaki M, Watanabe M, Suzuki T, Takahashi H, Nakamura A, McAllister F, Hishinuma T, Goto J, Lotze MT, Kolls JK, Sasaki H (2005) IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol 175:6177–6189PubMed

Oda Y, Yamamoto H, Tamiya S, Matsuda S, Tanaka K, Yokoyama R, Iwamoto Y, Tsuneyoshi M (2006) CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol 19:738–745PubMedCrossRef

Platsoucas CD, Fincke JE, Pappas J, Jung WJ, Heckel M, Schwarting R, Magira E, Monos D, Freedman RS (2003) Immune responses to human tumors: development of tumor vaccines. Anticancer Res 23:1969–1996PubMed

Poon RT, Fan ST, Wong J (2003) Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches. Ann Surg 238:9–28PubMedCrossRef

Scotlandi K, Serra M, Manara MC, Nanni P, Nicoletti G, Landuzzi L, Maurici D, Baldini N (1993) Human osteosarcoma cells, tumorigenic in nude mice, express beta1 integrins and low levels of alkaline phosphatase activity. Int J of Oncology 3:963–969

Staals EL, Bacchini P, Bertoni F (2006) Dedifferentiated central chondrosarcoma. Cancer 106:2682–2691PubMedCrossRef

Tuckermann JP, Pittois K, Partridge NC, Merregaert J, Angel P (2000) Collagenase-3 (MMP-13) and integral membrane protein 2a (Itm2a) are marker genes of chondrogenic/osteoblastic cells in bone formation: sequential temporal, and spatial expression of Itm2a, alkaline phosphatase, MMP-13, and osteocalcin in the mouse. J Bone Miner Res 15:1257–1265PubMedCrossRef

Udagawa T, Fernandez A, Achilles EG, Folkman J, D’Amato RJ (2002) Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy. FASEB J 16:1361–1370PubMedCrossRef

Yamazaki Y, Morita T (2006) Molecular and functional diversity of vascular endothelial growth factors. Mol Divers 10:515–527PubMedCrossRef

Title: Possible prognostic role of IL-17R in osteosarcoma
Authors: Maria Cristina Honorati
Luca Cattini
Andrea Facchini
Publication date: 01-12-2007
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 12/2007
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-007-0296-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2007

Treatment strategies that effectively reduce early recurrence risk in postmenopausal women with endocrine-sensitive breast cancer: AIs upfront vs. switching

Accuracy of clinical criteria for the diagnosis of hepatocellular carcinoma without biopsy in a Hepatitis B virus-endemic area

The influence of different microenvironments on melanoma invasiveness and microcirculation patterns: an animal experiment study in the mouse model

Diagnosis of basal cell carcinoma by infrared spectroscopy of whole blood samples applying soft independent modeling class analogy

A multigenic study on breast cancer risk associated with genetic polymorphisms of ER Alpha, COMT and CYP19 gene in BRCA1/BRCA2 negative Shanghai women with early onset breast cancer or affected relatives

Topoisomerase I protein expression in primary colorectal cancer and recurrences after 5-FU-based adjuvant chemotherapy

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials